Literature DB >> 27770265

Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey.

Giulia Marvaso1, Barbara Vischioni2, Barbara Alicja Jereczek-Fossa3,4, Delia Ciardo3, Piero Fossati5, Tommaso Giandini5, Sara Morlino6, Mauro Carrara7, Paola Romanelli3, Elvio Russi6, Francesca Valvo2, Riccardo Valdagni7,4, Roberto Orecchia4,8.   

Abstract

Hadrontherapy has been in constant progress in the past decades. Due to the increasing interest in this field and the spreading of the technique in Italy and worldwide, the Italian Society of Radiation Oncology surveyed (by an online survey) its members regarding their perception of hadrontherapy. The survey outline addressed different items all related to hadrontherapy, such as: demographics (3 items), personal knowledge (5 items), actual use in clinical practice (5 items), and future perspectives and development (5 items). The survey was filled in by 224 radiation oncologists (RO). Among them, 74.6 % were RO with more than 5 years of clinical practice, and only 10.4 % RO in training. Median age was 46 years (range 27-77). 32.24 % admitted average knowledge about heavy particles radiobiology rationale and 32.42 % about the ongoing particle therapy clinical trials. Radioresistant tumors are perceived as-principal indications for carbon ions in 39.3 % of responders, and pediatric malignancies for protons in 37 %. Re-irradiation is highly recommended for 52.2 %. Strikingly, 38.8 % of participating ROs reported that, in the daily clinical practice, approximately less than 1 out of 10 patients asks to be referred for hadrontherapy. On the other side, 35.7 % claimed need for at least 3 up to 5 particle therapy centers in Italy. Overall, the results of the present survey highlight the interest of the Italian RO community for particle therapy among the other radiotherapy technique. Analysis of our results might picture the clinical attitude of the RO community towards hadrontherapy in Italy, and help in promoting targeted initiatives to spread clinical results and knowledge about technical innovations in this field.

Entities:  

Keywords:  Carbon ion; Hadrontherapy; Proton therapy; Radiation oncologist; Survey

Mesh:

Substances:

Year:  2016        PMID: 27770265     DOI: 10.1007/s11547-016-0699-1

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  13 in total

1.  Should randomized clinical trials be required for proton radiotherapy? An alternative view.

Authors:  Eli Glatstein; John Glick; Larry Kaiser; Stephen M Hahn
Journal:  J Clin Oncol       Date:  2008-04-28       Impact factor: 44.544

Review 2.  Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience.

Authors:  Tadashi Kamada; Hirohiko Tsujii; Eleanor A Blakely; Jürgen Debus; Wilfried De Neve; Marco Durante; Oliver Jäkel; Ramona Mayer; Roberto Orecchia; Richard Pötter; Stanislav Vatnitsky; William T Chu
Journal:  Lancet Oncol       Date:  2015-02       Impact factor: 41.316

3.  In search of the economic sustainability of Hadron therapy: the real cost of setting up and operating a Hadron facility.

Authors:  Barbara Vanderstraeten; Jan Verstraete; Roger De Croock; Wilfried De Neve; Yolande Lievens
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-01       Impact factor: 7.038

Review 4.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

5.  Proton beam radiotherapy: report of the first ten patients treated at the "Centro Nazionale di Adroterapia Oncologica (CNAO)" for skull base and spine tumours.

Authors:  Roberto Orecchia; Viviana Vitolo; Maria Rosaria Fiore; Piero Fossati; Alberto Iannalfi; Barbara Vischioni; Anurita Srivastava; Jeffrey Tuan; Mario Ciocca; Silvia Molinelli; Alfredo Mirandola; Gloria Vilches; Andrea Mairani; Barbara Tagaste; Marco Riboldi; Giulia Fontana; Guido Baroni; Sandro Rossi; Marco Krengli
Journal:  Radiol Med       Date:  2013-12-12       Impact factor: 3.469

Review 6.  [Update of clinical programs using hadrontherapy 2008-2012].

Authors:  J-L Habrand; J Datchary; C Alapetite; S Bolle; V Calugaru; L Feuvret; S Helfre; D Stefan; S Delacroix; L Demarzi; R Dendale
Journal:  Cancer Radiother       Date:  2013-09-02       Impact factor: 1.018

Review 7.  Proton vs carbon ion beams in the definitive radiation treatment of cancer patients.

Authors:  Herman Suit; Thomas DeLaney; Saveli Goldberg; Harald Paganetti; Ben Clasie; Leo Gerweck; Andrzej Niemierko; Eric Hall; Jacob Flanz; Josh Hallman; Alexei Trofimov
Journal:  Radiother Oncol       Date:  2010-02-23       Impact factor: 6.280

8.  [Past, present and near future of techniques in radiation oncology].

Authors:  J-P Gérard; J Thariat; P Giraud; J-M Cosset
Journal:  Bull Cancer       Date:  2010-07       Impact factor: 1.276

9.  Controversies in clinical trials in proton radiotherapy: the present and the future.

Authors:  Robert C Miller; Mark Lodge; Mohammad Hassan Murad; Bleddyn Jones
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

Review 10.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more
  1 in total

1.  A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.

Authors:  Beatrice Ferrari; Elisa Roda; Erica Cecilia Priori; Fabrizio De Luca; Angelica Facoetti; Mauro Ravera; Federico Brandalise; Carlo Alessandro Locatelli; Paola Rossi; Maria Grazia Bottone
Journal:  Front Neurosci       Date:  2021-03-22       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.